Age 2–17 years | Quadrivalent LAIV |
Age 18–64 years (in clinical high-risk group due to illness, plus pregnant women, those in residential homes, carers, close contacts of immunocompromised) | Quadrivalent influenza vaccine: standard egg-grown or newly licensed cell-based vaccines |
Age ≥65 years | Adjuvanted trivalent influenza vaccine or cell-based quadrivalent influenza vaccine. High-dose trivalent vaccine is licensed, but not currently funded under the NHS as it has a significantly higher price |